Market Overview
Size path and containment premium
- Brevintel analysis values the global healthcare packaging market at USD 167.5 billion in 2025 ($167.5B), rising to USD 178.1 billion in 2026 and USD 323.4 billion by 2035 ($323.4B) at approximately 6.8% CAGR from 2026 to 2035 (about 6.85% on the longer trajectory).
- Headline cards list $167.5B, $323.4B, and 6.8%, aligning with the USD 167.5 billion to USD 323.4 billion narrative path through 2035.
- Smurfit WestRock led with over 6.83% market share in 2025; Amcor, Smurfit WestRock, Sonoco Products Company, CCL Industries, and Graphic Packaging collectively held 21.2%.
- Healthcare packaging spans primary containment, secondary information and protection systems, and tertiary distribution formats used for pharmaceuticals and medical devices.
- Demand is shaped by noncommunicable diseases, which caused at least 43 million deaths globally in 2021, and by sterile injectables, biologics, and temperature-sensitive therapies.
- Cardiovascular diseases caused 19 million deaths in 2021, cancers 10 million, chronic respiratory diseases 4 million, and diabetes more than 2 million, sustaining repeat medicine and packaging cycles.
- About 82% of premature noncommunicable-disease deaths occurred in low- and middle-income countries in 2021, linking emerging-market access expansion to packaging volume growth.
- Packaging performance is increasingly determined by product stability, contamination control, traceability, patient usability, and regulatory compliance rather than material cost alone.
Regulatory baseline and sustainability transition
- The EU Packaging and Packaging Waste Regulation entered into force in February 2025 and generally applies from August 2026, creating recyclable-design, recycled-content, and labeling obligations while retaining conditional provisions for contact-sensitive healthcare packaging.
- Pharmaceutical container-closure systems must demonstrate compatibility with the drug product throughout storage, transport, and intended use, including extractables, leachables, particulate risk, and closure integrity.
- Brevintel analysis indicates the market’s roughly 6.85% growth path masks a widening value gap between high-specification primary packaging and formats exposed to material substitution or logistics-led price competition.
- Injectable biologics and self-administered therapies require containers qualified for formulation compatibility, aseptic filling, delivery-device integration, and patient use.
- Recyclability requirements are most immediately actionable in cartons, labels, outer packs, and transport packaging, while sterile and contact-sensitive formats remain subject to conditional exemptions.
- Suppliers that can redesign secondary systems without compromising pharmaceutical information, tamper evidence, or line performance are positioned to capture conversion demand.
Market Dynamics
Drivers
- Regulation (EU) 2025/40 shifts sustainability from a procurement preference to a product-access issue for packaging placed on the EU market, directing earliest redesign toward secondary and tertiary formats.
- Cartons, leaflets, overwraps, and outer transport packs can be redesigned through fiber substitution, mono-material construction, recyclable coatings, and revised adhesives without changing direct drug-contact surfaces.
- Self-administration changes packaging from a passive barrier into part of the delivery system across pre-filled syringes, cartridges, autoinjector components, and on-body delivery formats.
- Gerresheimer reports injectable syringes have moved substantially from bulk toward ready-to-fill systems, extending that model to vials and cartridges through its EZ-fill platform.
- SCHOTT Pharma reported EUR 439 million in fiscal 2024 revenue from Drug Delivery Systems, up 28% year over year, reflecting demand for prefillable syringes and related injectable formats.
- Child resistance, tamper evidence, dose organization, and serialization create durable demand for technically specified secondary and primary packaging under U.S. Poison Prevention Packaging Act benchmarks.
- The FDA approved 18 biosimilars in 2024, bringing cumulative FDA-approved biosimilars to 63 across 17 reference products, each needing packaging qualified for formulation, storage, and delivery configuration.
- Biologic drugs impose exacting requirements for protein adsorption, glass delamination, stopper fragmentation, extractables, leachables, and container-closure integrity versus many oral solid-dose products.
Restraints and opportunity shape
- Emerging modalities—including antibody-drug conjugates, cell and gene therapies, mRNA products, and high-concentration subcutaneous formulations—lengthen commercialization through new compatibility, extractables and leachables, closure-integrity, and human-factors work.
- ICH Q1A(R2) stability-testing expectations mean a failed vial, stopper, syringe, or polymer system can force multiyear requalification, favoring suppliers with early development participation and established data packages.
- International frameworks provide reference points, but national rules can differ in pharmacopoeial references, labeling language, submission documentation, and recognition of foreign validation data.
- Regulatory fragmentation reduces efficiency of standardized global packaging programs and increases artwork variants, smaller production runs, and validation overhead.
- Brevintel analysis indicates chronic-disease treatment, biosimilar launches, and home-based administration expand addressable need, while biologic qualification requirements determine which suppliers convert that need into revenue.
- Qualification friction slows launch timing but also protects incumbents with validated materials, documented analytical performance, and integrated fill-finish relationships.
- Suppliers with modular platform designs, regional manufacturing, and disciplined artwork and serialization capabilities are better positioned to serve multinational and price-sensitive emerging-market requirements.
- The most attractive opportunity is validated injectable and secondary-pack capacity that meets clinical, regulatory, and recyclability constraints rather than undifferentiated conversion volume.
Segmentation Analysis
By material type
- Plastic is the largest material segment at USD 60,428 million in 2025 and grows at a 6.53% CAGR across PET liquid bottles, PE pouches and hospital bags, PP closures and sterilizable device packs, and PVC blister formats.
- Sustainability regulation is accelerating interest in PVC-free and lower-complexity blister structures, particularly in Europe, but replacement is constrained by barrier performance and established pharmaceutical-line compatibility.
- Glass is valued at USD 38,486 million in 2025 and advances at a 7.27% CAGR, with Type I borosilicate vials, ampoules, syringes, and cartridges central to sterile injectable and biologic packaging.
- Gerresheimer capacity investments and SCHOTT Pharma growth in prefillable delivery systems indicate injectable glass demand is supported by biologics, biosimilars, and self-administration formats.
- Paper and paperboard, valued at USD 32,546 million in 2025, is the fastest-growing material category at an 8.74% CAGR in cartons, inserts, protective components, and outer packs.
- Metals account for USD 21,337 million and grow at a 5.47% CAGR, led by aluminum foil and cold-form structures for moisture- and oxygen-sensitive oral dosage forms.
- The USD 14,701 million others category, growing at 3.97% CAGR, includes elastomeric closures, silicone components, specialty films, and composite laminates.
- Brevintel assessment suggests primary injectable packaging is the most defensible growth corridor because value is tied to clinical, regulatory, and manufacturing constraints rather than packaging volume alone.
By packaging type
- Primary packaging is the largest tier at USD 72,102 million in 2025 and records a 7.60% CAGR across bottles and jars, vials and ampoules, blister packs, pre-filled syringes, pouches, and tubes.
- The strongest value growth is concentrated in pre-filled syringes, cartridges, and ready-to-use vials, where sterile manufacturing compatibility and delivery-device integration raise qualification requirements.
- Secondary packaging totals USD 55,635 million in 2025 and grows at a 5.62% CAGR across cartons and boxes, labels and inserts, trays and sleeves, and overwraps.
- Secondary formats face the clearest sustainability redesign pressure because they are generally less constrained by direct drug contact than primary containment.
- Tertiary packaging reaches USD 39,762 million in 2025 and expands at a 7.06% CAGR as biologics, vaccines, and specialty medicines require validated temperature-controlled distribution.
- WHO pharmaceutical-packaging guidance highlights the need to protect product quality through storage and transport, making thermal performance and logistics validation central purchasing criteria for cold-chain formats.
By application
- Pharmaceuticals represent USD 106,864 million in 2025 and grow at a 7.18% CAGR, with oral drugs as the largest unit-volume application and injectable drugs driving disproportionate value through vials, ampoules, syringes, and cartridges.
- Topical and dermal drugs rely on tubes, jars, and dispensing systems; pulmonary medicines require specialized canister, valve, or device-related packaging; nasal products require spray-pump or unit-dose configurations.
- Medical devices total USD 60,634 million in 2025 and advance at a 6.24% CAGR across sterile-barrier pouches, trays, peelable lidding, and protective packaging for therapeutic, monitoring, and diagnostic equipment.
- Device-pack growth depends on healthcare utilization and diagnostic adoption and is generally less dependent on drug-specific stability testing than pharmaceutical containment.
- Paper and paperboard’s 8.74% CAGR reflects a structural shift in secondary packaging concentrated where fiber substitution does not compromise drug protection.
- Suppliers should distinguish recyclable secondary-pack conversion, which rewards material redesign and scale, from premium containment innovation, which rewards validation depth and specialized manufacturing.
Regional Outlook
North America and Europe
- North America is the largest regional market at USD 64,544 million in 2025 and is projected to reach USD 128,055 million by 2035, growing at a 7.14% CAGR.
- The United States accounts for USD 56,729 million in 2025 and grows at 7.42%, supported by biologic development, biosimilar approvals, self-administration demand, and child-resistant packaging requirements.
- Canada contributes USD 7,815 million and grows at 4.88%, with demand weighted toward technically aligned but comparatively cost-conscious pharmaceutical procurement.
- Europe is valued at USD 35,156 million in 2025 and is forecast to reach USD 63,875 million by 2035 at a 6.20% CAGR.
- Germany leads Europe at USD 8,957 million and grows at 7.72%, supported by its pharmaceutical manufacturing base and injectable-packaging capability.
- The UK reaches USD 6,639 million, France USD 5,695 million, Italy USD 4,657 million, Spain USD 3,388 million, and the rest of Europe USD 5,820 million in 2025.
- PPWR is Europe’s defining packaging-policy catalyst, accelerating secondary and tertiary redesign while conditional exemptions keep direct-contact formats on a cautious, evidence-based transition path.
- European suppliers able to combine recyclable material systems with regulatory-grade information management and validated performance have a timing advantage.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific totals USD 48,259 million in 2025 and is expected to reach USD 102,015 million by 2035, producing the highest regional CAGR of 7.82%.
- China is the largest country market at USD 18,620 million and grows at 8.53%; India follows at USD 10,183 million and approximately 8.1%.
- China’s pharmaceutical manufacturing scale and India’s export-oriented generic-drug base create demand for high-volume oral-dose packaging and internationally compliant formats.
- Japan, valued at USD 7,335 million, remains a high-specification market for sterile injectables, unit-dose formats, and medicines associated with an aging population.
- South Korea reaches USD 4,744 million, supported by biopharmaceutical export activity, while Australia/New Zealand and the rest of Asia Pacific total USD 2,873 million and USD 4,503 million, respectively.
- Latin America is valued at USD 15,322 million in 2025 and is projected to reach USD 23,283 million by 2035 at a 4.29% CAGR, with Brazil as the central market and Mexico benefiting from North American supply-chain proximity.
- The Middle East and Africa market is valued at USD 4,219 million in 2025 and is expected to reach USD 6,144 million by 2035, growing at a 3.84% CAGR.
- The UAE totals USD 1,297 million as a regional trading hub; Saudi Arabia is USD 1,042 million and grows at approximately 5.2%; South Africa represents USD 755 million; the rest of the region totals USD 1,125 million.
- Brevintel view: North America remains the higher-value environment for qualified injectable packaging, while Asia Pacific’s 7.82% CAGR makes it central to capacity allocation for export-oriented and domestic volume growth.
Competitive Landscape
Structure and share
- The market remains fragmented across global packaging groups, specialist injectable-containment suppliers, secondary-packaging converters, temperature-assurance providers, and labeling specialists.
- Smurfit WestRock holds an estimated 6.83% of global market revenue in 2025, followed by Amcor at approximately 5.87%, Graphic Packaging at 3.26%, CCL Industries at 2.94%, and Sonoco Products Company at 2.26%.
- Combined top-five share remains limited relative to total market value because customer requirements differ across materials, drug-delivery formats, sterile barriers, and regional supply chains.
- Amcor’s fiscal 2024 annual report recorded USD 13.6 billion in total sales and USD 10.3 billion in Flexibles sales, with operations spanning 212 locations in 40 countries.
- Gerresheimer fiscal 2024 revenue was EUR 2,035.9 million, with investments in syringes, ready-to-use vials, and the Bormioli Pharma acquisition strengthening biologics-oriented injectable exposure.
- SCHOTT Pharma reported fiscal 2024 revenue of EUR 957 million, with high-value solutions representing 55% of revenue and Drug Delivery Systems delivering EUR 439 million in sales.
- CCL Industries supplies specialty labels, expanded-content labels, security formats, and serialization-oriented systems; Graphic Packaging and Mayr-Melnhof Karton are positioned in fiber-based cartons and secondary packaging.
- Constantia Flexibles serves pharmaceutical flexible packaging including foil laminates, cold-form blister formats, and pouch structures; Sonoco Products Company participates through protective, rigid-paper, and medical-device-related applications.
Recent industry developments
- In October 2025, Amcor plc increased production capacity for recyclable and biodegradable pharmaceutical packaging solutions in response to demand for eco-friendly healthcare packaging.
- In November 2025, Amcor plc and Berry Global, Inc. completed an all-stock combination, expanding Amcor’s healthcare and consumer packaging footprint.
- In December 2025, DS Smith introduced TailorTemp, a temperature-controlled packaging solution for pharmaceutical and biotech products aimed at optimizing cold-chain logistics and supporting sustainability initiatives.
- In October 2025, Schott AG launched a next-generation polymer syringe system with tamper-evident design and optional RFID traceability to improve drug safety and inventory tracking.
- Aptar CSP Technologies focuses on active packaging and moisture and oxygen control; Cold Chain Technologies LLC, Peli BioThermal LLC, Sofrigam SA, and Cryopak Industries Inc. compete in temperature-assurance formats.
- Nelipak serves thermoformed sterile-barrier packaging for medical devices; Körber AG participates through packaging machinery, serialization, and automation; August Faller and Schreiner Group specialize in pharmaceutical cartons, inserts, and functional labels.
Integrated producers
- Amcor
- Smurfit WestRock
- Sonoco Products Company
- Graphic Packaging
- CCL Industries
- Mayr-Melnhof Karton
Specialty suppliers
- Gerresheimer
- SCHOTT Pharma
- Constantia Flexibles
- Aptar CSP Technologies
- Nelipak
- Körber AG
- August Faller GmbH & Co. KG
- Schreiner Group
- Cold Chain Technologies LLC
- Peli BioThermal LLC
- Sofrigam SA
- Cryopak Industries Inc.